目的 分析张家口市第一医院口服中成药使用情况,为临床合理用药提供参考。方法 从HIS中调取2019-2021年医院口服中成药的使用数据,采用Excel统计用药品种、用量、销售金额、计算其年增长率、用药频度(DDDs)和日均费用(DDC)。结果 2019-2021年,中成药处方量逐年增加,年增长率在10%左右;以不同类别口服中成药销售金额排序,祛瘀剂、扶正剂、清热剂、祛湿剂连续3年排在前4位;以DDDs排序,复方丹参滴丸、脑心通胶囊和银杏叶滴丸连续3年排序在前3位;以DDC排序,安宫牛黄丸连续3年排在首位。结论 医院口服中成药使用基本合理,但部分品种DDC较高,患者经济负担较大,须进一步加强管理。

Objective To analyze the use of oral Chinese patent medicines in First Hospital of Zhangjiakou City, and to provide reference for clinical rational drug use.Methods The service data of oral Chinese patent medicines in the hospital from 2019 to 2021 were retrieved from HIS, and Excel was used to count the drug variety, dosage, sales amount, and calculate its annual growth rate, DDDs, and DDC.Results From 2019 to 2021, the number of prescriptions of proprietary Chinese medicines increased year by year, with an annual growth rate of about 10%. In order of the sales amount of different types of oral proprietary Chinese medicines, stasisremoving agents, strengthening agents, heat-clearing agents, and damp-removing agents ranked top 4 for 3 consecutive years. In order of DDDs, Compound Danshen Dripping Pills, Naoxintong Capsules and Yinxingye Dropping Pills ranked the top 3 for 3 consecutive years. In terms of DDC, Angong Niuhuang Pills ranked top 1 for 3 consecutive years.Conclusion The use of oral Chinese patent medicines in the hospital is basically reasonable, but some varieties have higher DDC, and the economic burden of patients is relatively large, which needs to be further strengthened.

R288.6

河北省中医药管理局科研计划项目(2019536)